Liensinine

CAS# 2586-96-1

Liensinine

2D Structure

Catalog No. BCN6337----Order now to get a substantial discount!

Product Name & Size Price Stock
Liensinine: 5mg $58 In Stock
Liensinine: 10mg Please Inquire In Stock
Liensinine: 20mg Please Inquire Please Inquire
Liensinine: 50mg Please Inquire Please Inquire
Liensinine: 100mg Please Inquire Please Inquire
Liensinine: 200mg Please Inquire Please Inquire
Liensinine: 500mg Please Inquire Please Inquire
Liensinine: 1000mg Please Inquire Please Inquire

Quality Control of Liensinine

3D structure

Package In Stock

Liensinine

Number of papers citing our products

Chemical Properties of Liensinine

Cas No. 2586-96-1 SDF Download SDF
PubChem ID 160644 Appearance White powder
Formula C37H42N2O6 M.Wt 610.75
Type of Compound Alkaloids Storage Desiccate at -20°C
Solubility DMSO : 250 mg/mL (409.34 mM; Need ultrasonic)
Chemical Name 4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[[(1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]phenol
SMILES CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)O)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC
Standard InChIKey XCUCMLUTCAKSOZ-FIRIVFDPSA-N
Standard InChI InChI=1S/C37H42N2O6/c1-38-14-13-26-20-35(43-4)37(22-29(26)30(38)16-23-6-9-27(40)10-7-23)45-33-18-24(8-11-32(33)41)17-31-28-21-36(44-5)34(42-3)19-25(28)12-15-39(31)2/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3/t30-,31-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Liensinine

The plantule of Nelumbo nucifera Gaertn.

Biological Activity of Liensinine

DescriptionLiensinine is a human ether-a-go-go-related gene (hERG) inhibitor and a novel autophagy/mitophagy inhibitor, which can antagonize the ventricular arrhythmias. It exerts remarkable effect against thrombosis and possesses strong effect against platelet aggregation and coagulation.
TargetsP-gp | hERG | Autophagy
In vitro

[Effect of berberine, liensinine and neferine on HERG channel expression].[Pubmed: 23672049]

Zhongguo Zhong Yao Za Zhi. 2013 Jan;38(2):239-44.

Immunofluorescence and Western blot methods were adopted for qualitative and quantitative detections of the effect of different concentrations of berberine, Liensinine and neferine on the expression of stable transfection in HERG potassium channel in HEK-293 cells, as well as the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues, in order to investigate the anti-arrhythmic mechanism of berberine, Liensinine and neferine.
METHODS AND RESULTS:
Western blot method was used to detect protein expression of HERG channel in HERG-HEK cells. Immunofluorescence method as well as confocal laser microscope were used to detect the effect of different concentrations of berberine, Liensinine and neferine on protein expression of HERG channel. Western blot method was used to detect the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues as well as the effect of berberine, Liensinine and neferine on protein expression of stable transfection in HERG potassium channel in HEK-293 cells. Western blot experiment manifested that stable transfection of HEK293 cells containing HERG genes could increase protein expression of HERG channel. Berberine (10, 30 micromol x L(-1)) remarkably inhibited protein expression of HERG channel in HERG-HEK cells (P < 0.01). Berberine (10, 20 mg x kg(-1)) also inhibited protein expression of Ikr channel in rat ventricular tissues (P < 0.05). Liensinine (3, 10, 30 micromol x L(-1)) increased protein expression of HERG channel in HERG-HEK cells (P < 0.05). Neferine showed no effect on protein expression of HERG channel in HERG-HEK cells.
CONCLUSIONS:
The stably transfection of HERG-HEK cells can increase protein expression of HERG channel. Berberine shows inhibitory effect on protein expressions of in vitro HERG-HEK cells and Ikr channel in rat ventricular tissues. Liensinine improves protein expression of HERG channe in HERG-HEK cells. Neferine shows no effect on protein expression of HERG channel.

In vivo

A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission.[Pubmed: 26114658]

Autophagy. 2015;11(8):1259-79.

Autophagy inhibition has been widely accepted as a promising therapeutic strategy in cancer, while the lack of effective and specific autophagy inhibitors hinders its application.
METHODS AND RESULTS:
Here we found that Liensinine, a major isoquinoline alkaloid, inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. This effect is likely achieved via inhibiting the recruitment of RAB7A to lysosomes but not to autophagosomes. We further investigated the effects of autophagy inhibition by Liensinine on the therapeutic efficacy of chemotherapeutic drugs and found that cotreatment of Liensinine markedly decreased the viability and increased apoptosis in breast cancer cells treated with various chemotherapeutic agents. Mechanistically, we found that inhibition of autophagy/mitophagy by Liensinine enhanced doxorubicin-mediated apoptosis by triggering mitochondrial fission, which resulted from dephosphorylation and mitochondrial translocation of DNM1L. However, blocking autophagosome/mitophagosome formation by pharmacological or genetic approaches markedly attenuated mitochondrial fission and apoptosis in cells with combinatatorial treatment. Moreover, Liensinine was synergized with doxorubicin to inhibit tumor growth in MDA-MB-231 xenograft in vivo.
CONCLUSIONS:
Our findings suggest that Liensinine could potentially be further developed as a novel autophagy/mitophagy inhibitor, and a combination of Liensinine with classical chemotherapeutic drugs could represent a novel therapeutic strategy for treatment of breast cancer.

Protocol of Liensinine

Kinase Assay

Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.[Pubmed: 22508050]

Cell Physiol Biochem. 2012;29(3-4):431-42.

Liensinine and neferine, a kind of isoquinoline alkaloid, can antagonize the ventricular arrhythmias. The human ether-a-go-go-related gene (hERG) is involved in repolarization of cardiac action potential. We investigated the effects of Liensinine and neferine on the biophysical properties of hERG channel and the underlying structure-activity relationships.
METHODS AND RESULTS:
The effects of Liensinine and neferine were examined on the hERG channels in the stable transfected HEK293 cells using a whole-cell patch clamp technique, western blot analysis and immunofluorescence experiment. The pharmacokinetics and tissue distribution determination of Liensinine and neferine in rats were determined by a validated RP-HPLC method. Liensinine and neferine induced decrease of current amplitude in dose-dependent. Liensinine reduced hERG tail current from 70.3±6.3 pA/pF in control group to 56.7±2.8 pA/pF in the 1 μM group, 53.0±2.3 pA/pF (3 μM) and 17.8±0.7 pA/pF (30 μM); the corresponding current densities of neferine-treated cells were 41.9±3.1 pA/pF, 32.3±3.1 pA/pF and 16.2±0.6 pA/pF, respectively. Neferine had binding affinity for the open and inactivated state of hERG channel, Liensinine only bound to the open state. The inhibitory effects of Liensinine and neferine on hERG current were attenuated in the F656V or Y652A mutant channels. Neferine distributed more quickly than Liensinine in rats, which was found to be in higher concentration than Liensinine. Both Liensinine and neferine had no effect on the generation and expression of hERG channels. I
CONCLUSIONS:
n conclusion, neferine is a more potent blocker of hERG channels than Liensinine at low concentration (<10 μM), which may be due to higher hydrophobic nature of neferine compared with Liensinine. Neferine may be safety even for long-term treatment as an antiarrhythmic drug.

Cell Research

In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs.[Pubmed: 24036064]

J Ethnopharmacol. 2013 Nov 25;150(2):485-91.

Lotus plumule, the dried young cotyledon and radicle of the Nelumbo nucifera Gaertn. (Fam. Nymphaeaceae) ripe seed, is a famous Traditional Chinese Medicine to remove heat from the heart, anchor the mind, improve seminal emission, and arrest bleeding for centuries in China. Liensinine and its analogs neferine and isoLiensinine are the major active components in lotus plumule. Aim of the study is to investigate the association of Liensinine, neferine, and isoLiensinine with efflux transporters.
METHODS AND RESULTS:
Caco-2, MDCK, MDCK-MDR1, and MDCK-MRP2 were used as cell models for the transcellular transport and accumulation studies. The results obtained in Caco-2 cells suggested that P-glycoprotein (P-gp) might be involved in transcellular transport. Cellular accumulation and transport experiments were further performed in MDCK-MDR1 cells. GF120918 and cyclosporine A were found to completely inhibit the efflux, and the net efflux ratios of these alkaloids exhibited saturation over the concentration range. No significant differences in Liensinine accumulation and transport were observed between MDCK and MDCK-MRP2 cells.
CONCLUSIONS:
These results demonstrated that Liensinine, neferine, and isoLiensinine are substrates of P-gp, whereas MRP2 is not involved in the transport process, suggesting that P-gp might be responsible for the absorption and distribution of the 3 alkaloids.

Animal Research

Effects of liensinine on platelet aggregation and coagulability and thrombotic activity[Reference: WebLink]

Chinese Pharmacological Bulletin, 2010, 26(6):768-72.

To investigate the effects of Liensinine on platelet aggregation and coagulation function in rats,as well as the effect on experimental thrombosis.
METHODS AND RESULTS:
Inhibition rates of platelet aggregation for Liensinine in vivo were determined by the model of platelet aggregation induced by adenosine diphosphate.Coagulation time of mice was measured by capillary vessel method,and bleeding time of mice was measured by tail-cutting method.The effects of Liensinine were also evaluated on prothrombin time(PT),activated partial thromboplastin time(APTT)and thrombin time(TT).The model of artery-vein bypass thrombosis and Chandler's model were established to observe the effect of Liensinine. The result showed that Liensinine 5 and 10 mg·kg-1 had significant effect on inhibition of platelet aggregation and markedly prolonged bleeding time,coagulation time,PT,APTT and TT.Liensinine 5 and 10 mg·kg-1 inhibited the artery-vein bypass and Chandler's thrombus in different degree,reduced the thrombus weight significantly (either wet ordry).
CONCLUSIONS:
Liensinine exerts remarkable effect against thrombosis and possesses strong effect against platelet aggregation and coagulation.

Liensinine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Liensinine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Liensinine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6373 mL 8.1867 mL 16.3733 mL 32.7466 mL 40.9333 mL
5 mM 0.3275 mL 1.6373 mL 3.2747 mL 6.5493 mL 8.1867 mL
10 mM 0.1637 mL 0.8187 mL 1.6373 mL 3.2747 mL 4.0933 mL
50 mM 0.0327 mL 0.1637 mL 0.3275 mL 0.6549 mL 0.8187 mL
100 mM 0.0164 mL 0.0819 mL 0.1637 mL 0.3275 mL 0.4093 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Liensinine

A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission.[Pubmed:26114658]

Autophagy. 2015;11(8):1259-79.

Autophagy inhibition has been widely accepted as a promising therapeutic strategy in cancer, while the lack of effective and specific autophagy inhibitors hinders its application. Here we found that Liensinine, a major isoquinoline alkaloid, inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. This effect is likely achieved via inhibiting the recruitment of RAB7A to lysosomes but not to autophagosomes. We further investigated the effects of autophagy inhibition by Liensinine on the therapeutic efficacy of chemotherapeutic drugs and found that cotreatment of Liensinine markedly decreased the viability and increased apoptosis in breast cancer cells treated with various chemotherapeutic agents. Mechanistically, we found that inhibition of autophagy/mitophagy by Liensinine enhanced doxorubicin-mediated apoptosis by triggering mitochondrial fission, which resulted from dephosphorylation and mitochondrial translocation of DNM1L. However, blocking autophagosome/mitophagosome formation by pharmacological or genetic approaches markedly attenuated mitochondrial fission and apoptosis in cells with combinatatorial treatment. Moreover, Liensinine was synergized with doxorubicin to inhibit tumor growth in MDA-MB-231 xenograft in vivo. Our findings suggest that Liensinine could potentially be further developed as a novel autophagy/mitophagy inhibitor, and a combination of Liensinine with classical chemotherapeutic drugs could represent a novel therapeutic strategy for treatment of breast cancer.

In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs.[Pubmed:24036064]

J Ethnopharmacol. 2013 Nov 25;150(2):485-91.

ETHNOPHARMACOLOGICAL RELEVANCE: Lotus plumule, the dried young cotyledon and radicle of the Nelumbo nucifera Gaertn. (Fam. Nymphaeaceae) ripe seed, is a famous Traditional Chinese Medicine to remove heat from the heart, anchor the mind, improve seminal emission, and arrest bleeding for centuries in China. Liensinine and its analogs neferine and isoLiensinine are the major active components in lotus plumule. Aim of the study is to investigate the association of Liensinine, neferine, and isoLiensinine with efflux transporters. MATERIALS AND METHODS: Caco-2, MDCK, MDCK-MDR1, and MDCK-MRP2 were used as cell models for the transcellular transport and accumulation studies. RESULTS: The results obtained in Caco-2 cells suggested that P-glycoprotein (P-gp) might be involved in transcellular transport. Cellular accumulation and transport experiments were further performed in MDCK-MDR1 cells. GF120918 and cyclosporine A were found to completely inhibit the efflux, and the net efflux ratios of these alkaloids exhibited saturation over the concentration range. No significant differences in Liensinine accumulation and transport were observed between MDCK and MDCK-MRP2 cells. CONCLUSIONS: These results demonstrated that Liensinine, neferine, and isoLiensinine are substrates of P-gp, whereas MRP2 is not involved in the transport process, suggesting that P-gp might be responsible for the absorption and distribution of the 3 alkaloids.

Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.[Pubmed:22508050]

Cell Physiol Biochem. 2012;29(3-4):431-42.

Liensinine and neferine, a kind of isoquinoline alkaloid, can antagonize the ventricular arrhythmias. The human ether-a-go-go-related gene (hERG) is involved in repolarization of cardiac action potential. We investigated the effects of Liensinine and neferine on the biophysical properties of hERG channel and the underlying structure-activity relationships. The effects of Liensinine and neferine were examined on the hERG channels in the stable transfected HEK293 cells using a whole-cell patch clamp technique, western blot analysis and immunofluorescence experiment. The pharmacokinetics and tissue distribution determination of Liensinine and neferine in rats were determined by a validated RP-HPLC method. Liensinine and neferine induced decrease of current amplitude in dose-dependent. Liensinine reduced hERG tail current from 70.3+/-6.3 pA/pF in control group to 56.7+/-2.8 pA/pF in the 1 muM group, 53.0+/-2.3 pA/pF (3 muM) and 17.8+/-0.7 pA/pF (30 muM); the corresponding current densities of neferine-treated cells were 41.9+/-3.1 pA/pF, 32.3+/-3.1 pA/pF and 16.2+/-0.6 pA/pF, respectively. Neferine had binding affinity for the open and inactivated state of hERG channel, Liensinine only bound to the open state. The inhibitory effects of Liensinine and neferine on hERG current were attenuated in the F656V or Y652A mutant channels. Neferine distributed more quickly than Liensinine in rats, which was found to be in higher concentration than Liensinine. Both Liensinine and neferine had no effect on the generation and expression of hERG channels. In conclusion, neferine is a more potent blocker of hERG channels than Liensinine at low concentration (<10 muM), which may be due to higher hydrophobic nature of neferine compared with Liensinine. Neferine may be safety even for long-term treatment as an antiarrhythmic drug.

[Effect of berberine, liensinine and neferine on HERG channel expression].[Pubmed:23672049]

Zhongguo Zhong Yao Za Zhi. 2013 Jan;38(2):239-44.

OBJECTIVE: Immunofluorescence and Western blot methods were adopted for qualitative and quantitative detections of the effect of different concentrations of berberine, Liensinine and neferine on the expression of stable transfection in HERG potassium channel in HEK-293 cells, as well as the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues, in order to investigate the anti-arrhythmic mechanism of berberine, Liensinine and neferine. METHOD: Western blot method was used to detect protein expression of HERG channel in HERG-HEK cells. Immunofluorescence method as well as confocal laser microscope were used to detect the effect of different concentrations of berberine, Liensinine and neferine on protein expression of HERG channel. Western blot method was used to detect the effect of different concentrations of berberine on protein expression of Ikr channel in cardiac muscular tissues as well as the effect of berberine, Liensinine and neferine on protein expression of stable transfection in HERG potassium channel in HEK-293 cells. RESULT: Western blot experiment manifested that stable transfection of HEK293 cells containing HERG genes could increase protein expression of HERG channel. Berberine (10, 30 micromol x L(-1)) remarkably inhibited protein expression of HERG channel in HERG-HEK cells (P < 0.01). Berberine (10, 20 mg x kg(-1)) also inhibited protein expression of Ikr channel in rat ventricular tissues (P < 0.05). Liensinine (3, 10, 30 micromol x L(-1)) increased protein expression of HERG channel in HERG-HEK cells (P < 0.05). Neferine showed no effect on protein expression of HERG channel in HERG-HEK cells. CONCLUSION: The stably transfection of HERG-HEK cells can increase protein expression of HERG channel. Berberine shows inhibitory effect on protein expressions of in vitro HERG-HEK cells and Ikr channel in rat ventricular tissues. Liensinine improves protein expression of HERG channe in HERG-HEK cells. Neferine shows no effect on protein expression of HERG channel.

Description

Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.

Keywords:

Liensinine,2586-96-1,Natural Products, buy Liensinine , Liensinine supplier , purchase Liensinine , Liensinine cost , Liensinine manufacturer , order Liensinine , high purity Liensinine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: